Ensartinib or chemotherapy after surgery for alk-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial compares two treatments after lung cancer surgery: a new targeted drug (ensartinib) versus standard chemotherapy. The goal is to see if the targeted drug helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove your lung cancer within the last 10 weeks.
- Your cancer has a specific genetic change called ALK-positive.
- You are generally well enough to carry on with daily activities.
- You are expected to live at least 3 more months.
- You have not had other cancer in the last 5 years (except some minor skin cancers).
- You do not have active infections like hepatitis B or C, HIV, or a history of certain lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether taking ensartinib (a targeted pill) after lung cancer surgery can lower the chance the cancer comes back. It is for people with ALK-positive non-small cell lung cancer (NSCLC) whose cancer has been fully removed and who have recovered from treatment.
This trial tests the drug ensartinib to shrink lung cancer before surgery. It is for people with ALK-positive lung cancer that can be surgically removed.
This trial provides access to ensartinib, an oral medication that targets a specific genetic change in non-small cell lung cancer (NSCLC). It is for people who cannot join other clinical trials for ensartinib and may help control the cancer.
This trial tests different targeted therapies after surgery to lower the risk of early-stage lung cancer returning. It's designed for patients with high-risk features, and the treatment depends on the genetic changes in the tumor.
This trial tests whether taking ensartinib after surgery can lower the chance of lung cancer coming back in people whose tumors have a specific genetic change called ALK. The study uses a blood test called MRD to guide treatment.
This trial tests whether taking a pill called ensartinib after surgery can help prevent early stage lung cancer from coming back. It is for people whose tumors have a specific gene change called ALK and who have high-risk features.
Hear when a new Adjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.